Timely Initiation of Argatroban Improves Prognosis in Patients With Acute Ischemic Stroke Attributed to Large Artery Atherosclerosis: A Cohort Study

及时应用阿加曲班可改善大动脉粥样硬化所致急性缺血性卒中患者的预后:一项队列研究

阅读:1

Abstract

INTRODUCTION: Previous studies have demonstrated the benefits of anticoagulant therapy in acute ischemic stroke (AIS) of large artery atherosclerosis (LAA) etiology, although no prior research has examined the impact of the timing of anticoagulation initiation in this population. METHODS: A retrospective cohort study was conducted to assess the effect of early argatroban administration on clinical outcomes in AIS with LAA. Patients were stratified into an early administration group and a late administration group based on the time from stroke onset to argatroban initiation: ≤24 h and >24 h. The primary outcome was the proportion of favorable outcome, defined as modified Rankin Scale (mRS) score 0-2 at 90 days. Secondary outcomes included the proportion of patients achieving mRS 0-1 at 90 days, the mRS score at 90 days, and changes in National Institutes of Health Stroke Scale (NIHSS) score from baseline to 7 days or discharge. Safety outcomes comprised symptomatic intracranial hemorrhage (sICH), early neurological deterioration (END) during hospitalization, and organ hemorrhage within 90 days. Adjustments for potential confounders were performed using logistic regression. RESULTS: From February 2022 to February 2024, 401 AIS patients treated with argatroban were enrolled. After excluding patients with non-LAA etiologies, thrombolysis, and follow-up loss, 55 patients received argatroban ≤24 h after stroke onset, and 98 received it >24 h. At 90 days, 43.6% of the early administration group achieved favorable outcomes versus 27.6% of the later administration group (p = 0.024). One sICH occurred in the later administration group. END was observed in one (1.8%) patient in the early administration group and five (5.1%) in the later administration group. CONCLUSION: This is the first study to demonstrate that timely argatroban initiation may improve clinical outcomes in thrombolysis-naive patients with LAA AIS. However, the results should be interpreted with caution due to the study's retrospective design and limited sample size.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。